Post 2017, Baxter invested more than $70 million in cutting-edge manufacturing safety and quality systems, expanding its presence in the generic pharmaceuticals space.
Baxter Pharmaceuticals India Private Limited (BPIPL), Ahmedabad based generic injectables manufacturing facility has successfully completed five years of its robust presence in India. The company acquired a well-known generic injectables company for $625 million in 2017. The Baxter Ahmedabad facility is a cutting-edge generic injectables manufacturing facility that produces essential generic medicines with complementary strengths in anesthesia, analgesics, critical care, renal medicines, and anti-infectives in a variety of packaging formats such as vials, ampoules, and bags.
On the occasion, Rishikesh Jaiwant, Sr. Director – Manufacturing & Operations, Baxter Pharmaceuticals India Pvt. Ltd., said, "The past five years have been an evolutionary journey for Baxter Ahmedabad, and we have remained committed to the three pillars; safety first, quality always, and ethics and compliance in everything we do - that serve as the company's foundation. We take great pride in the fact that we are making a significant contribution to our mission of saving and sustaining lives globally. Going forward, we will continue to strive to be the best place to work for our employees, positively touch millions of lives with high quality healthcare products and remain committed to give back to the communities where we live and work."